Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

DNA molecule - entheon

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States. The Psychedelics Genetic Test Kit, a […]

Read More…

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Pine Point Mining signs agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement“) with Laboratorium Ofichem BV (“Ofichem” or “Ofichem Group”). Under the terms of the Agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine […]

Read More…